56 Article(s)Download |
PMID | Title | Pub. Year | #Total Relationships |
1 | 34953041 | Association of the programmed death ligand-1 combined positive score in tumors and clinicopathological features in esophageal cancer. | 2022 Feb | 1 |
2 | 35403870 | [Predictive immunocytochemistry in non-small cell lung carcinoma]. | 2022 May | 1 |
3 | 35562908 | PD-L1 Expression in Non-Small Cell Lung Cancer Specimens: Association with Clinicopathological Factors and Molecular Alterations. | 2022 Apr 19 | 1 |
4 | 35589508 | Malignant pleural effusion cell blocks are reliable resources for PD-L1 analysis in advanced lung adenocarcinomas: a concordance study with matched histologic samples. | 2022 Apr 22 | 1 |
5 | 33155793 | The importance of histological patterns on PD-L1 staining heterogeneity: Should we use pattern-based approach for selecting tumor samples for PD-L1 testing in lung adenocarcinomas? | 2021 Feb 26 | 1 |
6 | 33623414 | Relevance of PD-L1 Non-Coding Polymorphisms on the Prognosis of a Genetically Admixed NSCLC Cohort. | 2021 | 1 |
7 | 33683684 | Detection of Programmed Cell Death Ligand 1 Expression in Lung Cancer Clinical Samples by an Automated Immunohistochemistry System. | 2021 | 1 |
8 | 33683685 | Western Blot as a Support Technique for Immunohistochemistry to Detect Programmed Cell Death Ligand 1 Expression. | 2021 | 1 |
9 | 34178624 | Durable Response to the Combination of Atezolizumab With Platinum-Based Chemotherapy in an Untreated Non-Smoking Lung Adenocarcinoma Patient With BRAF V600E Mutation: A Case Report. | 2021 | 1 |
10 | 34206205 | Higher PD-L1 Immunohistochemical Detection Signal in Frozen Compared to Matched Paraffin-Embedded Formalin-Fixed Tissues. | 2021 Jun 22 | 1 |
11 | 34422362 | PD-L1 expression in non-small cell lung cancer: heterogeneity by pathologic types, tissue sampling and metastasis. | 2021 Jul | 1 |
12 | 34513680 | Incidence and Prognostic Significance of PD-L1 Expression in High-Grade Salivary Gland Carcinoma. | 2021 | 1 |
13 | 31605792 | Programmed Cell Death Ligand 1 Expression in Untreated EGFR Mutated Advanced NSCLC and Response to Osimertinib Versus Comparator in FLAURA. | 2020 Jan | 1 |
14 | 31987601 | Expression of PD-L1 in ovarian cancer and its synergistic antitumor effect with PARP inhibitor. | 2020 Apr | 1 |
15 | 32079442 | Prognostic impact of PD-L1 in oropharyngeal cancer after primary curative radiotherapy and relation to HPV and tobacco smoking. | 2020 Jun | 1 |
16 | 32333728 | PD-L1 expression in cell-blocks of non-small cell lung cancer: The impact of prolonged fixation. | 2020 Jul | 1 |
17 | 33241207 | Programmed Death Ligand 1 Expression in Laryngeal Squamous Cell Carcinomas and Prognosis. | 2020 Jan-Dec | 1 |
18 | 33299472 | Reliability of programmed death ligand 1 (PD-L1) tumor proportion score (TPS) on cytological smears in advanced non-small cell lung cancer: a prospective validation study. | 2020 | 2 |
19 | 29084060 | Characterization of PD-L1 Immunohistochemical Expression in Cell Blocks With Different Specimen Fixation and Processing Methods. | 2019 Feb | 1 |
20 | 29135534 | The Multiple Faces of Programmed Cell Death Ligand 1 Expression in Malignant and Nonmalignant Cells. | 2019 Apr | 3 |
21 | 29862664 | Programmed death receptor Ligand 1 expression in eyelid sebaceous carcinoma: a consecutive case series of 41 patients. | 2019 May | 1 |
22 | 31030490 | Programmed Death Ligand 1 (PD-L1) Expression in Epithelial Ovarian Cancer: A Comparison of Type I and Type II Tumors | 2019 Apr 29 | 1 |
23 | 31050216 | Immunocytochemistry for predictive biomarker testing in lung cancer cytology. | 2019 May | 1 |
24 | 31186735 | MicroRNAs aid the assessment of programmed death ligand 1 expression in patients with non-small cell lung cancer. | 2019 Jun | 1 |
25 | 31535805 | [Impact of PD-L1 status on the long-term outcomes of radical treatment of patients with prostate cancer]. | 2019 Sep | 1 |
26 | 28719380 | Comparison of Different Antibody Clones for Immunohistochemistry Detection of Programmed Cell Death Ligand 1 (PD-L1) on Non-Small Cell Lung Carcinoma. | 2018 Feb | 1 |
27 | 29189265 | Development of a Diagnostic Programmed Cell Death 1-Ligand 1 Immunohistochemistry Assay for Nivolumab Therapy in Melanoma. | 2018 Jan | 2 |
28 | 29491064 | Reduced Tumour Proportion Scores for Programmed Cell Death Ligand 1 in Stored Paraffin Tissue Sections. | 2018 Mar | 1 |
29 | 29713584 | PD-L1 testing using the clone 22C3 pharmDx kit for selection of patients with non-small cell lung cancer to receive immune checkpoint inhibitor therapy: are cytology cell blocks a viable option? | 2018 May-Jun | 1 |
30 | 29767258 | PD-L1 mRNA expression in EGFR-mutant lung adenocarcinoma. | 2018 Jul | 1 |
31 | 29938855 | Programmed death-ligand 1 immunoexpression in matched biopsy and liquid-based cytology samples of advanced stage non-small cell lung carcinomas. | 2018 Dec | 1 |
32 | 30121940 | Papillary Thyroid Carcinoma Emerging from Hashimoto Thyroiditis Demonstrates Increased PD-L1 Expression, Which Persists with Metastasis. | 2018 Dec | 1 |
33 | 30174892 | Clinical relevance of PD-L1 and PD-L2 overexpression in patients with esophageal squamous cell carcinoma. | 2018 Jul | 1 |
34 | 30323667 | Programmed death ligand 1 expression in human intrahepatic cholangiocarcinoma and its association with prognosis and CD8+ T-cell immune responses. | 2018 | 1 |
35 | 30386718 | Implications of Programmed Death Ligand-1 Positivity in Non-Clear Cell Renal Cell Carcinoma. | 2018 | 1 |
36 | 31043303 | The usefulness of various cytologic specimen preparations for PD-L1 immunostaining in non-small cell lung carcinoma. | 2018 Nov - Dec | 2 |
37 | 27667773 | An Analytical Comparison of Dako 28-8 PharmDx Assay and an E1L3N Laboratory-Developed Test in the Immunohistochemical Detection of Programmed Death-Ligand 1. | 2017 Feb | 2 |
38 | 28363612 | Programmed Death - Ligand 1 Expression Distinguishes Invasive Encapsulated Follicular Variant of Papillary Thyroid Carcinoma from Noninvasive Follicular Thyroid Neoplasm with Papillary-like Nuclear Features. | 2017 Apr | 1 |
39 | 28716437 | Tumor programmed cell death ligand 1 expression correlates with nodal metastasis in patients with cutaneous squamous cell carcinoma of the head and neck. | 2017 Sep | 1 |
40 | 28922567 | Determination of PD-L1 expression in effusions from mesothelioma by immuno-cytochemical staining. | 2017 Dec | 1 |
41 | 28978000 | PD-L1 expression in bladder cancer and metastasis and its influence on oncologic outcome after cystectomy. | 2017 Sep 15 | 1 |
42 | 26958083 | The Impact of PD-L1 Expression in Patients with Metastatic GEP-NETs. | 2016 | 1 |
43 | 27056074 | Prognostic effect of different PD-L1 expression patterns in squamous cell carcinoma and adenocarcinoma of the cervix. | 2016 Jul | 1 |
44 | 27166394 | Prognostic Value of Programmed Death Ligand 1 and Programmed Death 1 Expression in Thymic Carcinoma. | 2016 Sep 15 | 1 |
45 | 27333219 | Development of a Companion Diagnostic PD-L1 Immunohistochemistry Assay for Pembrolizumab Therapy in Non-Small-cell Lung Cancer. | 2016 Jul | 1 |
46 | 27564404 | An IL-27/Stat3 axis induces expression of programmed cell death 1 ligands (PD-L1/2) on infiltrating macrophages in lymphoma. | 2016 Nov | 2 |
47 | 27717372 | Development of a programmed cell death ligand-1 immunohistochemical assay validated for analysis of non-small cell lung cancer and head and neck squamous cell carcinoma. | 2016 Oct 8 | 1 |
48 | 27978870 | [Expression and Clinical Significance of PD-1 and PD-L1 in Pulmonary Carcinoids]. | 2016 Dec 20 | 1 |
49 | 26037795 | The status of PD-L1 and tumor-infiltrating immune cells predict resistance and poor prognosis in BRAFi-treated melanoma patients harboring mutant BRAFV600. | 2015 Sep | 1 |
50 | 26317305 | Development of an automated PD-L1 immunohistochemistry (IHC) assay for non-small cell lung cancer. | 2015 Sep | 2 |